Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Former hostage Eitan Mor on Hamas: ‘They will not give up until the last Israeli is gone' - 2Find the Interesting Universe of Computerized reasoning: the Capability of man-made intelligence
- 3Impact of NIH funding reductions felt in cancer and infectious disease trials
- 4Don’t let food poisoning crash your Thanksgiving dinner
- 5Hilary Duff releases 'Mature,' her 1st song in 10 years
- 19 Strange Motion pictures You Shouldn't Watch With Your Mum
- What to know as New York City nurses strike for a 3rd day
- The 10 Most Significant Virtual Entertainment Missions
- 'Backward and upward and tilted': Spaceflight causes astronauts' brains to shift inside their skulls
- Russian drone slams into block of flats in deadly wave of strikes across Kyiv
- 12 times rockets and spacecraft crashed and burned in 2025
- Taylor Momsen explains why she quit 'Gossip Girl': 'I really didn't want to be there'
- Indian rocket launches record-breaking BlueBird 6 smartphone satellite to orbit (video)
- What to expect from the planets in 2026 — key dates and sky events
